Germany Semaglutide Market Size & Outlook, 2024-2035
Related Markets
Germany semaglutide market highlights
- The Germany semaglutide market generated a revenue of USD 738.8 million in 2024 and is expected to reach USD 2,487.5 million by 2035.
- The Germany market is expected to grow at a CAGR of 10.2% from 2025 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2024.
- Wegovy (semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
Semaglutide market data book summary
| Market revenue in 2024 | USD 738.8 million |
| Market revenue in 2035 | USD 2,487.5 million |
| Growth rate | 10.2% (CAGR from 2025 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Wegovy (semaglutide) |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
Other key industry trends
- In terms of revenue, Germany accounted for 2.6% of the global semaglutide market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2035.
- In Europe, UK semaglutide market is projected to lead the regional market in terms of revenue in 2035.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 2,135.9 million by 2035.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Semaglutide Market Scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | http://www.lexpharma.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | https://www.vikingtherapeutics.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | http://www.biocon.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
Germany semaglutide market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 54.62% in 2024. Horizon Databook has segmented the Germany semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
Germany leads the Europe market due to its advanced biopharmaceutical manufacturing and robust healthcare system. Increasing adoption of GLP-1 receptor agonists for metabolic disorders and obesity fuels growth.
Hospital pharmacies dominate the distribution landscape, with online pharmacy expansion improving patient access to semaglutide-based therapies.
Reasons to subscribe to Germany semaglutide market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany semaglutide market databook
-
Our clientele includes a mix of semaglutide market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into Germany semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
Partial client list
Germany Product - Semaglutide Market size, 2024 - 2035 (US$M)
Germany Semaglutide Market Outlook Share, 2024 & 2035 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
